AstraZeneca gets US nod for expanded Imfinzi use, new rare-disease therapy
AZN•AstraZeneca said the FDA approved Imfinzi with enfortumab vedotin before surgery for certain patients with muscle-invasive bladder cancer, and approved Klygefa for adults with generalised myasthenia gravis. A late-stage trial showed the Imfinzi regimen cut cancer recurrence risk by 49% and death risk by 42%.
1. Two US approvals
The FDA approved Imfinzi combined with enfortumab vedotin before surgery for muscle-invasive bladder cancer patients who are ineligible for or have refused cisplatin-based chemotherapy. The approval was based on a late-stage trial that showed the regimen cut the risk of cancer recurrence by 49% and the risk of death by 42%.
2. Rare-disease treatment
The FDA also approved Klygefa, developed by AstraZeneca's rare disease unit Alexion, for adults with generalised myasthenia gravis who carry antibodies that disrupt communication between nerves and muscles. Klygefa also won approval in the EU for the same indication on Monday, adding to clearances in Japan and other countries for certain adults with gMG.




